Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M705116200 on September 11, 2007

J. Biol. Chem., Vol. 282, Issue 46, 33632-33640, November 16, 2007
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
282/46/33632    most recent
M705116200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, J.
Right arrow Articles by Zhang, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, J.
Right arrow Articles by Zhang, H.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Derepression of MicroRNA-mediated Protein Translation Inhibition by Apolipoprotein B mRNA-editing Enzyme Catalytic Polypeptide-like 3G (APOBEC3G) and Its Family Members*Formula

Jialing Huang, Zhihui Liang, Bin Yang, Heng Tian, Jin Ma, and Hui Zhang1

From the Center for Human Virology, Division of Infectious Diseases, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107

Received for publication, June 21, 2007 , and in revised form, August 10, 2007.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G (APOBEC3G or A3G) and its fellow cytidine deaminase family members are potent restrictive factors for human immunodeficiency virus type 1 (HIV-1) and many other retroviruses. A3G interacts with a vast spectrum of RNA-binding proteins and is located in processing bodies and stress granules. However, its cellular function remains to be further clarified. Using a luciferase reporter gene and green fluorescent protein reporter gene, we demonstrate that A3G and other APOBEC family members can counteract the inhibition of protein synthesis by various microRNAs (miRNAs) such as mir-10b, mir-16, mir-25, and let-7a. A3G could also enhance the expression level of miRNA-targeted mRNA. Further, A3G facilitated the association of microRNA-targeted mRNA with polysomes rather than with processing bodies. Intriguingly, experiments with a C288A/C291A A3G mutant indicated that this function of A3G is separable from its cytidine deaminase activity. Our findings suggest that the major cellular function of A3G, in addition to inhibiting the mobility of retrotransposons and replication of endogenous retroviruses, is most likely to prevent the decay of miRNA-targeted mRNA in processing bodies.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
MicroRNAs (miRNAs)2 are 20-22-nt regulatory RNAs that participate in the regulation of various biological functions in numerous eukaryotic lineages, including plants, insects, vertebrate, and mammals (1-3). More than 474 miRNAs have been identified in humans so far, and ~30% of the genes in the human genome are predicted to be subject to miRNA regulation (4). The expression of many miRNAs is usually specific to a tissue or developmental stage, and the miRNA expression pattern is altered during the development of many diseases (3). Mature miRNAs are generated from RNA polymerase II-transcribed primary miRNAs that are processed sequentially by the nucleases Drosha and Dicer. Although miRNA can guide mRNA cleavage, the basic function of miRNA is to mediate inhibition of protein translation (1, 5-8) through miRNA-induced silencing complexes (miRISCs). The guiding strand of miRNA in a miRISC interacts with a complementary sequence in the 3'-untranslated region (3'-UTR) of its target mRNA by partial sequence complementarities, resulting in translational inhibition (1). A 7-nucleotide "seed" sequence (at positions 2-8 from the 5'-end) in miRNAs seems to be essential for this action (4). The composition of the miRISC is similar to that of the RNA-induced silencing complex (RISC), which is responsible for mRNA cleavage guided by small interfering RNAs (siRNAs) (1, 3, 7). Nevertheless, some differences exist between miRISCs and siRNA RISCs. For example, the major Argonaute protein in siRNA RISC is Ago-2, whereas all four of the Ago proteins (Ago1-4) are found in miRISC (3, 8). Further, the siRNA RISC may be associated with various RNA-binding proteins such as fragile-X mental retardation protein (FMRP), TAR RNA-binding protein (TRBP), and the human homolog of the Drosophila helicase Armitage, Mov10, possibly in a cell type-specific manner (9-13).

The miRNA-mediated translational repression consistently correlates with an accumulation of miRNA-bound mRNAs at cytoplasmic foci known as processing bodies (P-bodies) (8). Several lines of evidence have indicated that P-bodies are actively involved in miRNA-mediated mRNA repression (14). The P-body-associated protein GW182 associates directly with Ago-1 (15, 16). Depletion of P-body components such as GW182 and Rck/p54 prevents translational repression of target mRNAs (8, 14-19). Furthermore, several miRISC-related components, such as miRNAs, mRNAs repressed by miRNAs, Ago-1, Ago-2, and Mov10, are found in P-bodies (14). P-body formation is a dynamic process that requires continuous accumulation of repressed mRNAs (20). However, P-bodies serve not only as sites for RNA degradation, but also for storage of repressed mRNAs (15). These mRNAs may later return to polysomes to synthesize new proteins (14). In fact, some cellular proteins can facilitate the exit of miRNA-bound mRNAs from P-bodies. For example, a stress situation may induce the relocation of HuR, an AU-rich element-binding protein, from the nucleus to P-bodies in the cytoplasm where it binds to the 3'-UTR of its target mRNA encoding CAT-1 (21). This binding increases the stability of the miR-122-bound mRNA by assisting it to egress from the P-body and return to polysomes. However, the mechanism underlying this reverse transport of miRNA-bound mRNA out of P-bodies remains to be further clarified.

The cellular apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G protein (APOBEC3G or A3G) is a potent antiretroviral factor that belongs to the cytidine deaminase family (22, 23). A3G can be incorporated into HIV-1 particles and cause extensive C to U conversion in the viral minus-stranded DNA during reverse transcription (24-26), which can trigger its degradation by virion-associated uracil DNA glycosylase-2 (UNG2) and apurinic/apyrimidinic endonucleases (APE) or lethal hypermutation in the HIV-1 genome (26, 27). However, accumulating evidence indicates that A3G protein carrying mutations in the catalytic domain of the cytidine deaminase retains substantial anti-HIV-1 activity (24, 28-31). Interestingly, A3G is found in P-bodies and stress granules (32, 33). It is associated with a high molecular mass structure (>700 kDa) in replicating cells, and this interaction is RNase-sensitive (34, 35). Further studies indicate that A3G interacts with many RNA-binding proteins, among which are several miRNA-related proteins, such as Ago1, Ago2, Mov10, and poly(A)-binding protein 1 (PABP1). These interactions are either partially or completely resistant to RNase A digestion (32, 35, 36).3 Aside from its inhibitory function in relation to endogenous retroviruses and other retrotransposons (37-41), the major cellular function of A3G seems to be related to P-body-related RNA processing and metabolism. As recent development has indicated that the function of P-body is closely related to miRNA activity, we therefore investigated the possibility of a connection between A3G and miRNA function.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Plasmid Constructions—The miRNA reporter constructs used in this study (pmir16-luc, pmir10b-luc, pmir25-luc, and pEGFP-c1-let-7a) were obtained by directly inserting the annealed corresponding miRNA-binding sites into the 3'-UTR region of the luciferase gene in the pMIR-REPORT vector (Ambion Inc., Austin, TX) between the SpeI and HindIII sites or into the 3'-UTR region of the green fluorescent protein gene, gfp, in the pEGFP-C1 vector (BD, Mountain View, CA) between the EcoRI and XhoI sites. A3B gene with a V5 epitope tag sequence at its 3' terminus was amplified from the mRNA of H9 cells through RT-PCR, and the sequence was confirmed. Then the modified A3B was inserted into the pcDNA3 vector. Wild-type and mutant A3G-expressing plasmids were amplified by PCR using constructs described previously as templates and cloned into the pcDNA3 vector (24). Detailed information about the oligonucleotides used for cloning or PCR is provided in supplemental Table S1.

Cell Isolation, Culture, and Transfection—Primary CD4+ T lymphocytes were isolated from peripheral blood mononuclear cells using the CD4+ T cell isolation kit II (Miltenyi, Auburn, CA) and subsequently activated by treating with phytohemagglutinin (PHA) (42). The purity of CD4 T-cells can reach 98%. For isolation of monocytes, CD14+ cells were purified from PBMCs by positive selection with CD14+ micromeads (Miltenyi, Auburn, CA) using auto MACS according to the manufacturer's instructions. The purity of the CD14+ cells is large than 98% as determined by FACS staining with CD14 antibody. Monocytes were further cultured in complete RPMI in the presence of 0.5 ng/ml recombinant human macrophage colony stimulating factor (M-CSF, R&D Systems) and 0.5 ng/ml granulocyte colony-stimulating factor (G-CSF, R&D Systems) for 7 days. The activated CD4+ T cells and H9 T cells were transfected using an Amaxa nucleofector apparatus (Amaxa Biosystems, Gaithersburg, MD), as described (42). 293T or HeLa cells were transfected using FuGENE 6 (Roche Applied Science, Indianapolis, IN) for plasmids or HiPerfect (Qiagen, Valencia, CA) for siRNAs or antisense miRNA inhibitors. Macrophages were transfected using jetPEI (Polyplus-Transfection Inc. New York, NY).

Synthesis of siRNAs and Antisense miRNA Inhibitors—The miRNA gene sequences were selected from the Sanger Center miRNA Registry. The siRNAs and synthetic antisense miRNA inhibitors (2'-O-methyl-oligoribonucleotides) against mir-16 and mir-28 were chemically synthesized by Integrated DNA Technologies (Coralville, IA).

miRNA Array Analysis—Total RNA (10 µg) from 293T cells transfected with pcDNA-A3G-HA or the pcDNA3 parent vector was isolated with TRIzol reagent (Invitrogen). The following RNA processing, microarray fabrication, array hybridization, and data acquisition were performed at LC Sciences (Houston, TX). Briefly, 2-5 µg of total RNA sample, which was size-fractionated using a YM-100 Microcon centrifugal filter (Millipore, Billerica, MA) and the small RNAs (<300 nt) isolated were 3'-extended with a poly(A) tail using poly(A) polymerase. An oligonucleotide tag was then ligated to the poly(A) tail for later fluorescent dye staining. Two different tags were used for the two RNA samples in dual-sample experiments. Hybridization was performed overnight on a Paraflo microfluidic chip using a microcirculation pump (Atactic Technologies, Houston, TX). On the microfluidic chip, each detection probe consisted of a chemically modified nucleotide coding segment complementary to target microRNA or other RNA (control or customer defined sequences) and a spacer segment of polyethylene glycol to extend the coding segment away from the substrate. Each region in the chip comprises a miRNA probe region, which detects miRNA transcripts listed in Sanger miRBase Release 9.0. Total 469 human miRNAs were tested. The detection probes were made by in situ synthesis using PGR (photogenerated reagent) chemistry. Hybridization used 100 µl of 6x SSPE buffer (0.90 M NaCl, 60 mM Na2HPO4, 6 mM EDTA, pH 6.8) containing 25% formamide at 34 °C. After hybridization detection used fluorescence labeling using tag-specific Cy3 and Cy5 dyes. Hybridization images were collected using a GenePix 4000B laser scanner (Molecular Device, Sunnyvale, CA) and digitized using Array-Pro image analysis software (Media Cybernetics, Bethesda, MD). Data were analyzed by first subtracting the background and then normalizing the signals using a LOWESS filter (Locally-weighted Regression). The ratio of the two sets of detected signals (log2 transformed, balanced) and p values of the t test were calculated; differentially detected signals were those with less than 0.01 p values.

Real-time RT-PCR Detection—To confirm the miRNA array results, "stem-loop" real-time reverse transcription (RT)-PCR was used to detect cellular miRNAs, as described, but with minor modifications (43). The primers for RT-PCR to detect miRNA were designed based on the miRNA sequences provided by the Sanger Center miRNA Registry (supplemental Table S1). The miRNAs were isolated from 293T cells with the mirVana miRNA isolation kit (Ambion). RT reactions were performed by means of the iScript cDNA synthesis kit (Bio-Rad). Real-time PCR was performed on the 7000 Sequence Detection System (Applied Biosystems, Foster City, CA). U6 RNA was used as an endogenous control for miRNA detection, while beta-actin or beta-tubulin mRNA was measured as an endogenous control for luciferase gene expression detection. The cycle number at which the product level exceeded an arbitrarily chosen threshold (CT) was determined for each target sequence, and the amount of each miRNA relative to U6 RNA (or luciferase to beta-actin mRNA) was described using the formula 2-{Delta}CT, where {Delta}CT = CT(miRNA (or luciferase) - CT U6 RNA (or beta-actin).

Flow Cytometric Analysis—Primary CD4+ T cells and H9 cells transfected with gfp-containing plasmids were subjected to flow cytometric analysis on a Beckman Coulter cytometer (Fullerton, CA) at 48 h post-nucleofection. The mean fluorescence intensity (MFI) and positive percentage rate (%) of green fluorescing cells was determined.

Luciferase Assay—A luciferase assay was performed as described (42).

Immunoprecipitation and Western Blotting—The co-immunoprecipitation analysis and Western blotting assays were performed as described (44). Rabbit polyclonal anti-A3G and anti-A3F antibodies were obtained from the National Institutes of Health AIDS Research and Reference Reagent Program.

Polysome Profile Analysis—Polysome profiles were determined as described with modifications (45). Briefly, 293T cells were cultured in Dulbecco's modified Eagle's medium, and treated with various reagents as indicated in the figure legend, and harvested at 48-h post-transfection at 70-80% confluency by replacing the culture media with fresh media containing cycloheximide (100 µg/ml; Sigma) for 30 min. Cells were washed with ice-cold phosphate-buffered saline (PBS) containing cycloheximide (50 µg/ml), followed by resuspension in an ice-cold lysis buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2, 2 units/µl RNasin, and 0.5% (v/v) Triton X-100 for 10 min. Nuclei and other cellular debris were then removed by centrifugation at 10,000 x g for 10 min at 4 °C. The supernatants were subsequently layered on top of 15-50% sucrose gradients. Centrifugation proceeded at 36,000 rpm for 90 min at 4 °C in a Beckmann SW41Ti rotor. The location of polysomes in the gradient was determined by measuring the absorbance at 254 nm using a spectrophotometer. RNAs in each fraction were extracted using TRIzol reagent and subjected to RT-PCR detection using primer pairs for the luciferase and beta-tubulin genes.

Immunofluorescence and in Situ Hybridization Analysis—For immunofluorescence analysis, HeLa cells were seeded onto coverslips in 6-well plates and transfected with 0.5 µg of pGFP-GW182delta1 plasmid (Addgene Inc., Cambridge, MA) (19) and 1 µg of pcDNA-A3G-HA using FuGENE 6. Cells were fixed at 36-h post-transfection with 4% paraformaldehyde for 30 min and permeabilized with 0.5% Triton X-100 for 5 min, followed by blocking in a buffer containing 0.2% Triton X-100, 100 mM Tris-HCl (pH 7.5), 0.9% NaCl, and 2% bovine serum albumin. Monoclonal anti-HA (Sigma) was used at 1:500 dilution, and a secondary goat anti-mouse antibody conjugated to Texas Red (Abcam, Cambridge, MA) was used at a dilution of 1:1000 for detection. The coverslips were analyzed with a Zeiss LSM 510 META Confocal Laser Scanning Microscope System (Thornwood, NY). For in situ hybridization analysis, HeLa cells growing on gelatin-coated coverslips were transfected with the pGFP-GW182delta1 plasmid and pmir-16-luc together with pcDNA-A3G-HA, pcDNA3, or various antisense anti-mir inhibitors, as indicated in the figure legend. At 48-h post-transfection, cells were fixed for 10 min at room temperature in 4% formaldehyde, 10% acetic acid, and PBS. After washing twice in PBS, cells were permeabilized by treatment with 70% ethanol overnight. Probes and coverslip were denatured at 80 °C for 75 s. After rehydration in 2x SSC, (300 mM NaCl, 30 mM sodium citrate, pH 7.0), 50% formamide, the fixed and permeabilized cells (~105) were hybridized for 1 h in a moist chamber at 37 °C in 40 µl of a mixture containing 10% dextran sulfate, 2 mM vanadyl-ribonucleoside complex, 0.02% RNase-free bovine serum albumin, 40 µg of Escherichia coli tRNA, 2x SSC, 50% formamide, and 10 µl of Cy3-labeled locked nucleic acid probes (Integrated DNA Technologies, Coralville, IA; for sequence of the probes, see supplemental Table S1), complementary to the luciferase coding regions diluted with 50% deionized formamide, 2x SSC, 10% dextran sulfate, 50 mM sodium phosphate (pH 7) to a final concentration of 10 nM. After washing three times for 5 min in a washing buffer containing 0.1x SSC and 50% formamide at 65 °C, followed by washing with PBS, the coverslips were mounted in antifade medium containing 0.1 µg/ml DAPI. Subsequently, the coverslips were analyzed with the Zeiss LSM 510 microscope.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
A3G Counteracts miRNA-mediated Repression of Protein Translation—We first examined the effect of A3G on the expression of miRNAs. Using a miRNA microarray method, we did not find that A3G significantly changed the miRNA expression in 293T cells (supplemental Figs. S1 and S2). A3G also did not significantly change the expression of miRNA processors such as Drosha and Dicer1 or RISC components such as Ago2 and Mov10 (supplemental Fig. S3). Further, A3G also did not change the level of expression of P-body components such as GW182, Xrn1 and Lsm1 (supplemental Fig. S3). Nevertheless, the microarray data did indicate that several miRNAs, such as mir-16, mir-10b, mir-25, and let-7a, are abundant in 293T cells.

To study whether A3G affects the efficiency of miRNA-mediated translational repression, various 293T cell-enriched miRNA-binding sites with perfect or partial complementarity to their corresponding miRNAs were inserted into the 3'-UTR of luciferase (luc) or gfp (Fig. 1a). These plasmids were transfected into 293T cells, which naturally do not express A3G (22, 27), with or without an A3G-HA-expressing plasmid. Fig. 1b shows that the presence of mir-16, mir-10b, or mir-25 miRNA-binding sites in the 3'-UTR of luc gene remarkably inhibited the expression of luciferase. Interestingly, A3G significantly counteracted this inhibition. Similar phenomenon can be observed in HeLa cells (Fig. 1c). To verify this derepression, a dose dependence experiment was performed and derepression was found to correlate with the A3G expression level (Fig. 1d). Real-time PCR data showed that the expression level of luciferase mRNA also substantially increased concomitantly with the expression level of A3G (Fig. 1e). This derepression of miRNA-mediated translational inhibition still occurred when the reporter gene was changed to gfp (Fig. 1f).


Figure 1
View larger version (25K):
[in this window]
[in a new window]

  		FIGURE 1.
A3G counteracts miRNA-mediated repression of protein translation in 293T and HeLa cells. a, sequences of the miRNAs mir-16, mir-25, mir-10b, and let-7a and their target sites used for reporter gene constructs are shown. b and c, 293T cells (b) or HeLa cells (c) were co-transfected with a plasmid expressing A3G (pcDNA-A3G-HA) and a plasmid containing the luciferase reporter gene with binding sites for mir-16, mir-10b, or mir-25 in the 3'-UTR. pcDNA3 and pmir-REPORT were also transfected as controls. At 48-h post-transfection, luciferase activity was measured. d and e, 293T cells were co-transfected with different amounts of A3G-expressing plasmid (ranging from 0 to 0.4 µg) and pmir16-luc. At 48-h post-transfection, luciferase activity (d) was measured, and luciferase mRNA (e) was detected by real-time RT-PCR. The means ± S.D. are shown. f, 293T cells were co-transfected with pcDNA-A3G-HA and a plasmid containing a GFP reporter gene with a binding site for let-7a in the 3'-UTR, pEGFP-c1-let-7a, or pEGFP-c1 as a control. At 48-h post-transfection, GFP expression was analyzed by FACS and the mean fluorescence intensity (MFI) of GFP was determined. The data shown are representative of at least three replicates.

 


Figure 2
View larger version (12K):
[in this window]
[in a new window]

  		FIGURE 2.
A3G/F-specific siRNA restores miRNA-mediated repression of protein translation in A3G/F-rich T-lymphocytes and macrophages. PHA-activated CD4+ T cells (a) and H9 cells (b) were first transfected with A3G- and A3F-specific siRNAs via Nucleofector (AMAXA). A siRNA for luc was used as a control for transfection. After 48 h, the cells were transfected with pEGFP-c1-let-7a or pEGFP-c1. At 48-h post-transfection, GFP expression was analyzed by FACS. The MFI of GFP from pEGFP-c1 was set as 100%. The means ± S.D. are shown. c, primary monocyte-derived macrophages were first transfected with A3G- and A3F-specific siRNAs. A siRNA for luc was used as a control for transfection. After 48 h, the cells were transfected with pEGFP-c1-let-7a or pEGFP-c1. pcDNA3-A3G-HA (2 µg) was also cotransfected for overexpression experiment. At 48-h post-transfection, GFP expression was analyzed by Western blotting analysis via anti-GFP antibody. The expression of A3G and A3F were also examined by Western blotting.

 


Figure 3
View larger version (16K):
[in this window]
[in a new window]

  		FIGURE 3.
APOBEC3 family members inhibit miRNA-mediated repression of protein translation. 293T cells were co-transfected with plasmids expressing APOBEC3 family members and pmir16-luc (a) or with plasmids expressing various A3G mutants and pmir16-luc (b). At 48-h post-transfection, luciferase activity was measured. The 4C mutant represents an A3G mutant that has four point mutations: C97A/C100A/C288A/C291A. The means ± S.D. are shown.

 
Furthermore, to confirm this effect, H9 T-cells, PHA-activated primary CD4+ T-lymphocytes and macrophages, which naturally harbor significant amounts of A3G and another APO-BEC3 protein, A3F, were treated with A3G- and A3F-specific siRNAs. Western blotting showed that expression of A3G and A3F could be effectively decreased by these siRNAs (Fig. 2, a-c). The depletion of A3G and A3F enhanced the efficiency of let-7a miRNA-mediated translational repression in these A3G/F-enriched cells (Fig. 2, a-c). Conversely, overexpression of A3G/F in macrophages can substantially enhance the derepression of miRNA-mediated translational inhibition (Fig. 2c, lane 1).

Other APOBEC3 Family Members Also Inhibit miRNA-mediated Repression of Protein Translation—To test whether other APOBEC3 family members also regulate miRNA repression, vectors expressing the APOBEC3 family members A3B, A3C, and A3F were transfected into 293T cells. All the tested APOBEC3 family members were able to inhibit the miRNA-mediated translational repression (Fig. 3a). Interestingly, a synergistic effect was found between various APOBEC3 family members (Fig. 3a).


Figure 4
View larger version (24K):
[in this window]
[in a new window]

  		FIGURE 4.
A3G enhances the association of mir-16-targeted mRNA with polysomes. 293T cells were co-transfected with pMIR-REPORT and pcDNA3 (a), pMIR-REPORT and pcDNA3-A3G (b), pmir16-luc and pcDNA3 (c), pmir16-luc and pcDNA3-A3G (d), pmir16-luc and anti-mir16 inhibitors (e), or pmir16-luc and anti-mir28 inhibitors (f). At 48-h post-transfection, polysome profile analysis was performed and the distribution of luciferase mRNA and beta-tubulin mRNA in the fractions was analyzed by RT-PCR. 293T cells were co-transfected with pmir16-luc and pcDNA3-A3G (g), or pMIR-REPORT alone (h). Prior to collection, the cells were treated with puromycin (0.3 mg/ml) for 30 min. At 48-h post-transfection, polysome profile analysis was performed, and the distribution of luciferase and beta-tubulin mRNA in the fractions was analyzed by RT-PCR.

 
Given that A3G has cytidine deaminase activity, we examined whether this activity is responsible for the A3G inhibitory effect on miRNA translational repression. Mutation in the N-terminal zinc-binding domain of A3G important for virion incorporation and mutation in the C-terminal zinc-binding domain important for cytidine deaminase activity were examined for their possible influence on miRNA-mediated translational repression (28-31). The mutations that inactivate the N-terminal domain, C97A and C100A, had a modest effect on miRNA-mediated translational repression, whereas the C-terminal domain C288A and C291A mutations had no significant influence on the inhibitory effect of A3G (Fig. 3b), suggesting that the cytidine deaminase activity is unlikely involved in this effect.

A3G Enhances the Association of miRNA-targeted mRNA with Polysomes—To examine whether the A3G inhibitory effect on mir-16-mediated repression was at the level of translation, a polysome profile analysis was performed (Fig. 4). As shown in Fig. 4c, mir-16 decreased the association of its target mRNA with polysomes, which is consistent with previous reports (45, 46). However, A3G, as well as an antisense anti-mir-16 inhibitor, significantly enhanced the association of the target mRNA with polysomes (Fig. 4, d and e). Puromycin treatment can disrupt this association, further confirming the complex that luciferase mRNA bound with is polysome (Fig. 4g).

A3G Facilitates the Dissociation of miRNA-targeted mRNA from P-bodies—As A3G can be found in P-bodies (32, 33), and can increase the amount of miRNA-targeted mRNA (Fig. 1e), we then investigated whether A3G could be directly associated with GW182, a key component for P-body. We found that A3G can interact with GW182. This interaction is partially resistant to RNase digestion. Mutation at C-terminal catalytic domain of A3G (C288A/C291A) cannot eliminate this interaction (Fig. 5a). Further, we also confirmed that A3G co-localized with GW182 (Fig. 5b) (32, 33). Moreover, we have found that the depletion of GW182 with GW182-specific siRNA had a synergistic effect with A3G in counteracting miRNA-mediated translational repression (Fig. 5c), which is consistent with previous reports regarding the role of GW182 in miRNA function (15, 16).

We then examined whether A3G had any effect on the interaction between miRNA-targeted mRNA and P-bodies by performing in situ hybridization with confocal microscopy, as described (21). The location of luciferase mRNA was detected with a Cy3-conjugated oligonucleotide probe, and the location of P-bodies was visualized with GFP-GW182 (19). The mRNA without miRNA-binding sites did not associate with GW182 (Fig. 6, a and b). In the absence of A3G, mir-16-targeted luciferase mRNA was found associated with GW182 and in P-bodies (Fig. 6c), indicating that miRNAs such as mir-16 mediate the association of mRNA with P-bodies. However, in the presence of A3G, mir-16-targeted luciferase mRNA was not found in the P-body (Fig. 6d), suggesting that A3G either facilitates the exit of miRNA-bound mRNA from P-bodies or prevents miRNA-bound mRNA from entering P-bodies. As a control, an anti-mir-16 antisense inhibitor, which can specifically block the function of mir-16, but not an anti-mir28 inhibitor, also prevented the miRNA-targeted luciferase mRNA from associating with GW182 and P-bodies (Fig. 6, e and f).


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
In this report, we have found that the APOBEC3 family protein A3G significantly counteracts the translational inhibition of several miRNAs: mir-10b, mir-16, mir-25, and let-7a in 293 T and HeLa cells. This effect can be found when A3G is expressed at a low level (0.1 µg of pcDNA3-A3G-HA) (Fig. 1, d and e). As such, it is unlikely that this phenomenon is a consequence of over-expression of A3G. Other APOBEC3 family members, such as A3B, A3C, and A3F, also had a similar function, and the family members had a synergistic inhibitory effect with A3G, indicating that it is a conserved function of APOBEC3 family proteins. Given that A3G localizes to P-bodies and stress granules and interacts with many RNA-binding proteins, such as Ago1, Ago2, Mov10, GW182, and PABP1 (32, 35, 36),3 we suggest that A3G and other APOBEC3 family members participate in regulating miRNA-mediated translational repression.


Figure 5
View larger version (22K):
[in this window]
[in a new window]

  		FIGURE 5.
Interaction between A3G and GW182. a, 293T cells were transfected with pcDNA3-A3G-HA or pcDNA3-A3G-C97A/C100A-HA. At 48-h post-transfection, cells were collected and lysed. Lysates were treated with and without RNase A, followed by immunoprecipitation with mouse anti-GW182 antibody. The precipitated samples were then subjected to SDS-PAGE electrophoresis. After transferring, A3G was detected with rabbit anti-A3G antibody. b, HeLa cells were co-transfected with pcDNA-A3G-HA and pGFP-GW182delta1 (19). At 48-h post-transfection, the localization of GW182 was visualized with GFP-GW182 fluorescence (green) and A3G was detected with mouse anti-A3G and visualized with Texas Red-conjugated goat anti-mouse antibody (red). c, 293T cells were transfected with GW182-specific siRNA. At 48-h post-transfection, the cells were co-transfected with pcDNA-A3G-HA and pmir16-luc. After another 48 h, a luciferase assay was performed. The means ± S.D. are shown.

 


Figure 6
View larger version (71K):
[in this window]
[in a new window]

  		FIGURE 6.
A3G facilitates the dissociation of mir-16-targeted mRNA from P-bodies. HeLa cells were co-transfected with pcDNA-A3G-HA, pmir16-luc, pGFP-GW182delta1, or various antisense miRNA inhibitors, as indicated. At 48-h post-transfection, P-bodies were visualized with GFP-GW182 fluorescence (green), and luciferase mRNA was visualized by in situ hybridization with Cy3-conjugated oligonucleotide probes (red). DAPI staining of the nuclei is shown in blue. A magnification of the regions enclosed by the boxes is shown in the insets at the upper left corners.

 
Endogenous A3G can be found in various cells such as H9 T-cells, primary CD4 T-cells, macrophages, and many other normal tissues/organs such as spleen, thymus, testis, ovary, small intestine, mucosal lining of colon (22, 47). They can effectively inhibit the replication of vif-defective HIV-1 (22, 48, 49). Although miRNAs are still able to mediate translational inhibition in H9 T-cells, primary CD4 T-cells at a moderate level and in macrophage at a significant level, we believe that their activity has been restricted by endogenous A3G/A3F. As shown in Fig. 2, a-c, A3G/F-specific siRNAs, which effectively deplete A3G/F in these cells, can significantly further enhance the miRNA-mediated translational inhibition, indicating endogenous A3G or A3F are functional to prevent the activity of miRNA. Furthermore, overexpression of A3G/F can effectively counteract the miRNA-mediated inhibitory effect on translation, supporting this argument (Fig. 2c). Nevertheless, the result from overexpression of exogenous A3G/F also suggests that the either quantity or quality of endogenous A3G/F could need to be improved for an efficient counteraction to miRNA activity. Recently, we and others have found that interferon-(IFN)-{alpha}/beta can significantly enhance the expression of A3G/F in various primary cells such as resting CD4 T-lymphocytes, macrophages, endothelial cells, hepatocytes, myeloid dendritic cells, and plasmacytoid dendritic cells (42, 50-54).3 Therefore, it is interesting to further investigate the correlation of IFN regulatory system and the miRNA activity in these primary cells.

Our data demonstrate that A3G facilitates recruitment of miRNA-targeted mRNA to polysomes to synthesize more proteins and drives dissociation of miRNA-targeted mRNA from P-bodies. Given that A3G is associated with mRNA, localizes to P-bodies and stress granules (32, 33, 36), and can substantially enhance the expression of miRNA-targeted mRNA (Fig. 1e), it is unlikely that A3G directly improves the interaction between mRNA and polysomes or inhibits the interaction between miRNA and its target mRNA in miRISC. Instead, A3G may block miRNA-targeted mRNA from entering P-bodies or stress granules, may prevent the miRNA-targeted mRNA from engaging the RNA degradation machinery in P-bodies, or may directly facilitate the egress of miRNA-targeted mRNA from P-bodies and stress granules. By one or more of these approaches, A3G may inhibit the degradation or storage of miRNA-targeted miRNA in P-bodies and stress granules. Subsequently, more of the mRNA could associate with polysomes, and the translation efficiency would therefore be enhanced. However, as the mechanism of the regulation of mRNA degradation and storage in P-bodies or stress granules remains to be clarified and the relationship between miRNA-mediated translational repression and P-bodies is still under intensive investigation, further experiments are required to demonstrate the exact mechanism underlying this cellular function of A3G.

Interestingly, the mutations C228A and C291A inactivated the cytidine deaminase activity of A3G, but A3G was still able to enhance the expression of luciferase when luc was controlled by miRNA (Fig. 3b). Therefore, the derepression of miRNA-mediated inhibition of protein translation by A3G is separable from its cytidine deaminase activity. As described in many reports, the cytidine deaminase activity of A3G is only partially responsible for viral infectivity (24, 28-31). It remains to be determined whether this cellular function of A3G in protein translation regulation is related to its cytidine deaminase-independent antiviral activity.


   FOOTNOTES
 
* This work was supported in part by National Institutes of Health Grants AI058798 and AI052732 (to H. Z.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

Formula The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1-S3 and Table S1. Back

1 To whom correspondence should be addressed: JAH334, Thomas Jefferson University, 1020 Locust St., Philadelphia, PA 19107. Tel.: 215-503-0163; E-mail: hui.zhang{at}jefferson.edu.

2 The abbreviations used are: miRNA, microRNA; nt, nucleotide; miRISC, miRNA-induced silencing complexe; siRNA, small interfering RNA; UTR, untranslated region; HA, hemagglutinin; PBS, phosphate-buffered saline; RT, reverse transcriptase; FACS, fluorescence-activated cell sorter; PHA, phytohemagglutinin; DAPI, 4',6-diamidino-2-phenylindole; GFP, green fluorescent protein; APOBEC3G, apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G; HIV-1, human immunodeficiency virus type 1; P-bodies, processing bodies. Back

3 H. Zhang, unpublished data. Back


   ACKNOWLEDGMENTS
 
We obtained pcDNA3.1-A3C-V5-6xHis, pcDNA3.1-A3F-V5-6xHis, and rabbit polyclonal anti-A3G and anti-A3F antibodies from the National Institutes of Health AIDS Research and Reference Reagent Program, pGFP-GW182delta1 from Dr. E. K. Chan in University of Florida.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Bartel, D. P. (2004) Cell 116, 281-297[CrossRef][Medline] [Order article via Infotrieve]
  2. Ambros, V., and Chen, X. (2007) Development 134, 1635-1641[Abstract/Free Full Text]
  3. Rana, T. M. (2007) Nat. Rev. Mol. Cell. Biol. 8, 23-36[CrossRef][Medline] [Order article via Infotrieve]
  4. Lewis, B. P., Burge, C. B., and Bartel, D. P. (2005) Cell 120, 15-20[CrossRef][Medline] [Order article via Infotrieve]
  5. Hutvagner, G., and Zamore, P. D. (2002) Science 297, 2056-2060[Abstract/Free Full Text]
  6. Meister, G., Landthaler, M., Patkaniowska, A., Dorsett, Y., Teng, G., and Tuschl, T. (2004) Mol. Cell 15, 185-197[CrossRef][Medline] [Order article via Infotrieve]
  7. Ambros, V., Lee, R. C., Lavanway, A., Williams, P. T., and Jewell, D. (2003) Curr. Biol. 13, 807-818[CrossRef][Medline] [Order article via Infotrieve]
  8. Pillai, R. S., Bhattacharyya, S. N., and Filipowicz, W. (2007) Trends Cell Biol. 17, 118-126[Medline] [Order article via Infotrieve]
  9. Chendrimada, T. P., Gregory, R. I., Kumaraswamy, E., Norman, J., Cooch, N., Nishikura, K., and Shiekhattar, R. (2005) Nature 436, 740-744[CrossRef][Medline] [Order article via Infotrieve]
  10. Gregory, R. I., Chendrimada, T. P., Cooch, N., and Shiekhattar, R. (2005) Cell 123, 631-640[CrossRef][Medline] [Order article via Infotrieve]
  11. Caudy, A. A., Myers, M., Hannon, G. J., and Hammond, S. M. (2002) Genes Dev. 16, 2491-2496[Abstract/Free Full Text]
  12. Lee, Y., Hur, I., Park, S. Y., Kim, Y. K., Suh, M. R., and Kim, V. N. (2006) EMBO J. 25, 522-532[CrossRef][Medline] [Order article via Infotrieve]
  13. Meister, G., Landthaler, M., Peters, L., Chen, P. Y., Urlaub, H., Luhrmann, R., and Tuschl, T. (2005) Curr. Biol. 15, 2149-2155[CrossRef][Medline] [Order article via Infotrieve]
  14. Eulalio, A., Behm-Ansmant, I., and Izaurralde, E. (2007) Nat. Rev. Mol. Cell. Biol. 8, 9-22[CrossRef][Medline] [Order article via Infotrieve]
  15. Liu, J., Rivas, F. V., Wohlschlegel, J., Yates, J. R., 3rd, Parker, R., and Hannon, G. J. (2005) Nat. Cell Biol. 7, 1261-1266[Medline] [Order article via Infotrieve]
  16. Behm-Ansmant, I., Rehwinkel, J., Doerks, T., Stark, A., Bork, P., and Izaurralde, E. (2006) Genes Dev. 20, 1885-1898[Abstract/Free Full Text]
  17. Bruno, I., and Wilkinson, M. F. (2006) Cell 125, 1036-1038[CrossRef][Medline] [Order article via Infotrieve]
  18. Chu, C. Y., and Rana, T. M. (2006) PLoS Biol. 4, e210[CrossRef][Medline] [Order article via Infotrieve]
  19. Jakymiw, A., Lian, S., Eystathioy, T., Li, S., Satoh, M., Hamel, J. C., Fritzler, M. J., and Chan, E. K. (2005) Nat. Cell Biol. 7, 1267-1274[Medline] [Order article via Infotrieve]
  20. Eulalio, A., Behm-Ansmant, I., Schweizer, D., and Izaurralde, E. (2007) Mol. Cell. Biol. 27, 3970-3981[Abstract/Free Full Text]
  21. Bhattacharyya, S. N., Habermacher, R., Martine, U., Closs, E. I., and Filipowicz, W. (2006) Cell 125, 1111-1124[CrossRef][Medline] [Order article via Infotrieve]
  22. Sheehy, A. M., Gaddis, N. C., Choi, J. D., and Malim, M. H. (2002) Nature 418, 646-650[CrossRef][Medline] [Order article via Infotrieve]
  23. Turelli, P., and Trono, D. (2005) Science 307, 1061-1065[Abstract/Free Full Text]
  24. Zhang, H., Yang, B., Pomerantz, R. J., Zhang, C., Arunachalam, S. C., and Gao, L. (2003) Nature 424, 94-98[CrossRef][Medline] [Order article via Infotrieve]
  25. Mangeat, B., Turelli, P., Caron, G., Friedli, M., Perrin, L., and Trono, D. (2003) Nature 424, 99-103[CrossRef][Medline] [Order article via Infotrieve]
  26. Yu, Q., Konig, R., Pillai, S., Chiles, K., Kearney, M., Palmer, S., Richman, D., Coffin, J. M., and Landau, N. R. (2004) Nat. Struct. Mol. Biol. 11, 435-442[CrossRef][Medline] [Order article via Infotrieve]
  27. Yang, B., Chen, K., Zhang, C., Huang, S., and Zhang, H. (2007) J. Biol. Chem. 282, 11667-11675[Abstract/Free Full Text]
  28. Newman, E. N., Holmes, R. K., Craig, H. M., Klein, K. C., Lingappa, J. R., Malim, M. H., and Sheehy, A. M. (2005) Curr. Biol. 15, 166-170[CrossRef][Medline] [Order article via Infotrieve]
  29. Bogerd, H. P., Wiegand, H. L., Doehle, B. P., and Cullen, B. R. (2007) Virology 364, 486-493[CrossRef][Medline] [Order article via Infotrieve]
  30. Holmes, R. K., Koning, F. A., Bishop, K. N., and Malim, M. H. (2007) J. Biol. Chem. 282, 2587-2595[Abstract/Free Full Text]
  31. Bishop, K. N., Holmes, R. K., and Malim, M. H. (2006) J. Virol. 80, 8450-8458[Abstract/Free Full Text]
  32. Gallois-Montbrun, S., Kramer, B., Swanson, C. M., Byers, H., Lynham, S., Ward, M., and Malim, M. H. (2007) J. Virol. 81, 2165-2178[Abstract/Free Full Text]
  33. Wichroski, M. J., Robb, G. B., and Rana, T. M. (2006) PLoS Pathog. 2, e41[CrossRef][Medline] [Order article via Infotrieve]
  34. Chiu, Y. L., Soros, V. B., Kreisberg, J. F., Stopak, K., Yonemoto, W., and Greene, W. C. (2005) Nature 435, 108-114[CrossRef][Medline] [Order article via Infotrieve]
  35. Chiu, Y. L., Witkowska, H. E., Hall, S. C., Santiago, M., Soros, V. B., Esnault, C., Heidmann, T., and Greene, W. C. (2006) Proc. Natl. Acad. Sci. U. S. A. 103, 15588-15593[Abstract/Free Full Text]
  36. Kozak, S. L., Marin, M., Rose, K. M., Bystrom, C., and Kabat, D. (2006) J. Biol. Chem. 281, 29105-29119[Abstract/Free Full Text]
  37. Esnault, C., Heidmann, O., Delebecque, F., Dewannieux, M., Ribet, D., Hance, A. J., Heidmann, T., and Schwartz, O. (2005) Nature 433, 430-433[CrossRef][Medline] [Order article via Infotrieve]
  38. Bogerd, H. P., Wiegand, H. L., Doehle, B. P., Lueders, K. K., and Cullen, B. R. (2006) Nucleic Acids Res. 34, 89-95[Abstract/Free Full Text]
  39. Hulme, A. E., Bogerd, H. P., Cullen, B. R., and Moran, J. V. (2007) Gene (Amst.) 390, 199-205[CrossRef][Medline] [Order article via Infotrieve]
  40. Dutko, J. A., Schafer, A., Kenny, A. E., Cullen, B. R., and Curcio, M. J. (2005) Curr. Biol. 15, 661-666[CrossRef][Medline] [Order article via Infotrieve]
  41. Esnault, C., Millet, J., Schwartz, O., and Heidmann, T. (2006) Nucleic Acids Res. 34, 1522-1531[Abstract/Free Full Text]
  42. Chen, K., Huang, J., Zhang, C., Huang, S., Nunnari, G., Wang, F. X., Tong, X., Gao, L., Nikisher, K., and Zhang, H. (2006) J. Virol. 80, 7645-7657[Abstract/Free Full Text]
  43. Chen, C., Ridzon, D. A., Broomer, A. J., Zhou, Z., Lee, D. H., Nguyen, J. T., Barbisin, M., Xu, N. L., Mahuvakar, V. R., Andersen, M. R., Lao, K. Q., Livak, K. J., and Guegler, K. J. (2005) Nucleic Acids Res. 33, e179[Abstract/Free Full Text]
  44. Yang, S., Sun, Y., and Zhang, H. (2001) J. Biol. Chem. 276, 4889-4893[Abstract/Free Full Text]
  45. Nottrott, S., Simard, M. J., and Richter, J. D. (2006) Nat. Struct. Mol. Biol. 13, 1108-1114[CrossRef][Medline] [Order article via Infotrieve]
  46. Pillai, R. S., Bhattacharyya, S. N., Artus, C. G., Zoller, T., Cougot, N., Basyuk, E., Bertrand, E., and Filipowicz, W. (2005) Science 309, 1573-1576[Abstract/Free Full Text]
  47. Jarmuz, A., Chester, A., Bayliss, J., Gisbourne, J., Dunham, I., Scott, J., and Navaratnam, N. (2002) Genomics 79, 285-296[CrossRef][Medline] [Order article via Infotrieve]
  48. Gabuzda, D. H., Lawrence, K., Langhoff, E., Terwilliger, E., Dorfman, T., Haseltine, W. A., and Sodroski, J. (1992) J. Virol. 66, 6489-6495[Abstract/Free Full Text]
  49. Zheng, Y. H., Irwin, D., Kurosu, T., Tokunaga, K., Sata, T., and Peterlin, B. M. (2004) J. Virol. 78, 6073-6076[Abstract/Free Full Text]
  50. Tanaka, Y., Marusawa, H., Seno, H., Matsumoto, Y., Ueda, Y., Kodama, Y., Endo, Y., Yamauchi, J., Matsumoto, T., Takaori-Kondo, A., Ikai, I., and Chiba, T. (2006) Biochem. Biophys. Res. Commun. 341, 314-319[CrossRef][Medline] [Order article via Infotrieve]
  51. Peng, G., Lei, K. J., Jin, W., Greenwell-Wild, T., and Wahl, S. M. (2006) J. Exp. Med. 203, 41-46[Abstract/Free Full Text]
  52. Bonvin, M., Achermann, F., Greeve, I., Stroka, D., Keogh, A., Inderbitzin, D., Candinas, D., Sommer, P., Wain-Hobson, S., Vartanian, J. P., and Greeve, J. (2006) Hepatology 43, 1364-1374[CrossRef][Medline] [Order article via Infotrieve]
  53. Sarkis, P. T., Ying, S., Xu, R., and Yu, X. F. (2006) J. Immunol. 177, 4530-4540[Abstract/Free Full Text]
  54. Argyris, E. G., Acheampong, E., Wang, F., Huang, J., Chen, K., Mukhtar, M., and Zhang, H. (2007) Virology in press

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 RNAHome page
J. T. Zipprich, S. Bhattacharyya, H. Mathys, and W. Filipowicz
Importance of the C-terminal domain of the human GW182 protein TNRC6C for translational repression
RNA, May 1, 2009; 15(5): 781 - 793.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
A. K. Khatua, H. E. Taylor, J. E. K. Hildreth, and W. Popik
Exosomes Packaging APOBEC3G Confer Human Immunodeficiency Virus Resistance to Recipient Cells
J. Virol., January 15, 2009; 83(2): 512 - 521.
[Abstract] [Full Text] [PDF]

Home page
 Genome ResHome page
J. G. Reid, A. K. Nagaraja, F. C. Lynn, R. B. Drabek, D. M. Muzny, C. A. Shaw, M. K. Weiss, A. O. Naghavi, M. Khan, H. Zhu, et al.
Mouse let-7 miRNA populations exhibit RNA editing that is constrained in the 5'-seed/ cleavage/anchor regions and stabilize predicted mmu-let-7a:mRNA duplexes
Genome Res., October 1, 2008; 18(10): 1571 - 1581.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
Q. Liu, H. Fu, F. Sun, H. Zhang, Y. Tie, J. Zhu, R. Xing, Z. Sun, and X. Zheng
miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes
Nucleic Acids Res., September 1, 2008; 36(16): 5391 - 5404.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
S. Gallois-Montbrun, R. K. Holmes, C. M. Swanson, M. Fernandez-Ocana, H. L. Byers, M. A. Ward, and M. H. Malim
Comparison of Cellular Ribonucleoprotein Complexes Associated with the APOBEC3F and APOBEC3G Antiviral Proteins
J. Virol., June 1, 2008; 82(11): 5636 - 5642.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
A. Hudder and R. F. Novak
miRNAs: Effectors of Environmental Influences on Gene Expression and Disease
Toxicol. Sci., June 1, 2008; 103(2): 228 - 240.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
282/46/33632    most recent
M705116200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, J.
Right arrow Articles by Zhang, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, J.
Right arrow Articles by Zhang, H.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement